The in vivo anti-tumour activity of volasertib was assessed in comparison with the CDK4/6 inhibitor palbociclib and the FGFR1/2/3 inhibitor AZD45479, as monotherapies or in combination with fulvestrant. Here, CDK4 is linked to neoplasm.